Health-Related QOL Study in Patients with CCA

2022 Year in Review - Cholangiocarcinoma - Cholangiocarcinoma

Data related to health-related quality of life (QOL), including financial toxicity, for patients with cholangiocarcinoma (CCA) who are receiving targeted therapies are limited. Researchers from the Winship Cancer Institute, Emory University, Atlanta, GA, in association with the Cholangiocarcinoma Foundation (CCF), conducted a patient-reported health-related QOL study to gain insight into the effect of physical, psychosocial, and financial challenges in patients with CCA. Dr Keilson presented the results at the 2022 ASCO GI Cancers Symposium.

Through the CCF, patients with CCA completed 2 validated QOL surveys—the FACT (Functional Assessment of Cancer Therapy)-Hepatobiliary and the COST (Comprehensive Score for Financial Toxicity) surveys. Subscales included physical well-being, social well-being, emotional well-being, functional well-being, hepatobiliary cancer subscale, and financial toxicity scale, and composite FACT scores of these subscales were calculated according to the Manual of Functional Assessment of Chronic Illness Therapy.

A total of 208 patients completed the surveys. Of these, 156 (75%) patients had intrahepatic CCA and 52 (25%) patients had extrahepatic CCA; 96 patients had early-stage disease, 70 had locally advanced disease, and 42 patients had metastatic CCA. Of the 119 (57%) patients with CCA who underwent resection, 56 (48%) had disease recurrence. Overall, 45 (22%) patients enrolled in a clinical trial, 167 (80%) patients had molecular profiling, and 48 (29%) patients received targeted therapy.

Based on the domains of physical, social, emotional, and functional well-being, the QOL scores were similar between patients enrolled in a clinical trial and patients who were not enrolled; however, the patients enrolled in a clinical trial reported higher financial burden (effect size, 0.33; P = .05). Similarly, patients who received targeted therapy reported similar QOL but higher financial toxicity than patients who did not receive targeted therapy (effect size, 0.43; P = .01).

Dr Keilson and colleagues concluded that based on these data, clinical trial enrollment and targeted therapies do not affect a patient’s physical, emotional, social, or functional well-being; however, these strategies are associated with an increased financial burden on patients with CCA. This is because, although the therapies used in clinical trials are not paid by the patient, the majority of patients with CCA are enrolled in clinical trials with late-stage disease, when they have already accumulated significant costs. The investigators noted that this highlights the need to increase access to clinical trials and personal therapies for patients with CCA to remove financial barriers.

Source: Keilson JM, Lindsey S, Bachini M, et al. Patient report outcomes: financial toxicity in cholangiocarcinoma. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2022. Abstract 394.

Related Items
Key Advances in the Treatment of Patients with BTC in 2023: New Targeted Therapies, Potential Biomarkers, and Combination Strategies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: